Sanofi stock slumps after two setbacks on multiple-sclerosis drug

by | Dec 15, 2025 | Stock Market

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and that a trial for a different form of MS didn’t succeed.

Article Attribution | Read More at Article Source